Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme (porphyrin) preparation presented as a sterile solution for injection for intravenous use. It is employed to treat acute intermittent porphyria and other acute hepatic porphyrias by providing exogenous heme that suppresses the over‑production of neurotoxic porphyrin precursors during attacks.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide. The company ensures product quality, regulatory compliance and cold‑chain logistics where required.

Normosang is used in the management of acute hepatic porphyria attacks by supplying heme to down‑regulate the porphyrin biosynthetic pathway.

- Acute intermittent porphyria: reduces accumulation of neurotoxic precursors and helps terminate acute attacks. - Hereditary coproporphyria: provides exogenous heme to suppress aminolevulinic acid synthase activity during crises. - Variegate porphyria: assists in controlling porphyrin precursor buildup in acute episodes.

Normosang may be associated with a range of adverse reactions, most of which are related to its intravenous administration and heme content.

Common Side Effects: - Pain at injection site: mild to moderate discomfort during or after infusion. - Phlebitis: inflammation of the vein used for administration. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache during treatment. - Fever: low‑grade temperature rise. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hemolysis: rapid breakdown of red blood cells, especially in patients with G6PD deficiency. - Methemoglobinemia: elevated methemoglobin levels leading to cyanosis and hypoxia. - Renal impairment: decreased kidney function observed in rare cases. - Severe hypotension: sudden drop in blood pressure during infusion. - Thromboembolic events: rare clot formation in veins or arteries.

When using Normosang, several precautions should be observed to minimize risks and ensure safe administration. - Patient assessment: evaluate for G6PD deficiency and history of hypersensitivity before infusion. - Monitoring: observe vital signs and for signs of anaphylaxis during and after administration. - Infusion rate: administer slowly as recommended to reduce phlebitis and systemic reactions. - Concomitant drugs: avoid concurrent use of strong oxidizing agents that may increase oxidative stress. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang can interact with other medicines, affecting either its efficacy or the safety profile of the co‑administered drug.

Major Interactions (Avoid): - Strong oxidizing agents: may exacerbate oxidative stress and increase risk of hemolysis. - Porphyrin‑inducing drugs (e.g., barbiturates, sulfonamides): can counteract the therapeutic effect of heme supplementation.

Moderate Interactions (Monitor Closely): - Anticoagulants: hemin may alter coagulation parameters; monitor INR or aPTT. - Anticonvulsants: some agents may affect porphyrin metabolism; observe clinical response. - Vitamin D analogues: potential for altered calcium metabolism; check serum levels.